ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Nefopam and Morphine Consumption in the Treatment of Ureteral Calculi

This study is not yet open for participant recruitment.
Verified by University Hospital, Clermont-Ferrand, March 2008

Sponsored by: University Hospital, Clermont-Ferrand
Information provided by: University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT00639574
  Purpose

The administration of néfopam after initial treatment by kétoproféne, could obtain, in patients remaining pain and classically need morphine, analgesia at least the same as morphine alone. The use of néfopam second line after ketoprofen could reducing (or even eliminating) the need for morphine (and its side effects), allowing a reduction in the length of stay of patients in the emergency unit.

The main objective is to show that the addition of a néfopam initial treatment with the kétoproféne, reduces, in patients with ureteral calculi, the percentage of patients requiring the use of a treatment by morphine.

The secondary objective is to reduce the side effects caused by the morphine, shorten the time to install the appropriate level of analgesia while reducing the risk of failure of the titration morphine, reduce the time spent on titration of morphine and reduce the length of stay patient intake in emergency unit.


Condition Intervention Phase
Ureteral Calculi, Hyperalgic, Not Complicated
Drug: Néfopam
Phase IV

ChemIDplus related topics:   Ketoprofen    Nefopam    Nefopam hydrochloride   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:   Interest of Néfopam in the Treatment of Pain During the Intense Ureteral Calculi Uncomplicated in Adults in Emergencies Unit.

Further study details as provided by University Hospital, Clermont-Ferrand:

Primary Outcome Measures:
  • Need to use morphine as an analgesic scheme (binary yes/no) [ Time Frame: as analgesic scheme ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • -Quantity of morphine consumed after titration (mg and number of bolus) -Pain (measured by the EVA) after administration of placebo or néfopam -Simplified verbal Scale of Satisfaction [ Time Frame: after titration and after administration of placebo or néfopam ] [ Designated as safety issue: No ]

Estimated Enrollment:   52
Study Start Date:   March 2008
Estimated Study Completion Date:   January 2009
Estimated Primary Completion Date:   November 2008 (Final data collection date for primary outcome measure)

Intervention Details:
    Drug: Néfopam

    There are two groups :

    • a group N : néfopam
    • a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes.
Detailed Description:

The study is prospective, parallel, double-blind, randomized, placebo-controlled analysis with intent to treat. There are 2 groups:

  • A group N: néfopam
  • A group P: placebo And all the patient receive, before randomization, 100 mg of ketoprofen (Profenid ®) on 20 minutes.

The number of subjects is 52.

  Eligibility
Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • • Age between 18 to 50 years old.

    • Admitted to the emergency room for typical ureteral calculi with severe pain (VAS > or = 60), and microscopic hematuria in the strip without signs of urinary complications
    • Preliminary Agreement patient

Exclusion Criteria:

  • • patient disagree

    • Pregnant women (sought by the questioning)
    • Fever> 38 ° C,
    • Leucocyturie or nitriturie (dipstick)
    • Contraindication to ketoprofen
    • Contraindication to néfopam
    • Contraindication to morphine
    • Contraindication linked to drug interactions as mentioned in the Summary of Product Characteristics of the Authorization for placing on the market of Acupan ®.
    • Treatment opioid analgesics, nonsteroidal anti-inflammatory or inflammatory or paracetamol in the previous 12 hours.
    • Secondary exclusion to a urinary tract infection or systemic.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00639574

Contacts
Contact: Patrick Lacarin     04.73.75.1195     placarin@chu-clermontferrand.fr    

Sponsors and Collaborators
University Hospital, Clermont-Ferrand

Investigators
Principal Investigator:     Moustafa Fares, Dr     University Hospital, Clermont-Ferrand    
  More Information

Responsible Party:   CHU Clermont-Ferrand ( Moustafa Farès )
Study ID Numbers:   CHU-0030
First Received:   March 14, 2008
Last Updated:   March 19, 2008
ClinicalTrials.gov Identifier:   NCT00639574
Health Authority:   France: Ministry of Health

Keywords provided by University Hospital, Clermont-Ferrand:
Pain, morphine, nefopam, co analgesia, ureteral calculi, emergency  

Study placed in the following topic categories:
Pathological Conditions, Anatomical
Urinary Calculi
Ketoprofen
Morphine
Urolithiasis
Ureteral Calculi
Ureteral Diseases
Pain
Calculi
Nefopam
Ureterolithiasis
Urologic Diseases
Emergencies

Additional relevant MeSH terms:
Sensory System Agents
Analgesics, Non-Narcotic
Therapeutic Uses
Physiological Effects of Drugs
Peripheral Nervous System Agents
Analgesics
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 29, 2008




Links to all studies - primarily for crawlers